TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06038409

Intervention type: DRUG
Intervention: Ketamine
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Intervention type: DRUG
Intervention: Ketamine
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Intervention type: DRUG
Intervention: Ketamine
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Intervention type: DRUG
Intervention: Ketamine
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
Study: NCT05271604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ozuriftamab Vedotin
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evalstotug (BA3071)
Description: Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evalstotug (BA3071)
Description: Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor (EGFR) antagonist
Study: NCT05935670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
Study: NCT06465589

Intervention type: OTHER
Group type: OTHER
Intervention: JOURNeY anonymous
Description: The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JOURNeY anonymous
Description: The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life.

Intervention type: OTHER
Group type: OTHER
Intervention: JOURNeY standard
Description: The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: JOURNeY standard
Description: The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life.
Study: NCT05296473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD Therapy
Description: investigational game-play therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: control game-play therapy
Study: NCT05992883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
Study: NCT05763043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
Study: NCT04576988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background PAH Therapy
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background PAH Therapy
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Study: NCT05810740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: Binimetinib 15 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: Binimetinib 15 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 MG
Description: Binimetinib 45 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 MG
Description: Binimetinib 45 mg tablet
Study: NCT05264857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thyroid Nodule Management Education
Description: Participants will receive information about thyroid nodules and their management
Study: NCT05499910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NSBAA
Description: The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
Study: NCT04525755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 MG
Description: varenicline comes in bottles of 56 - 0.5 mg pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: 28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
Study: NCT06062290

Intervention type: DEVICE
Intervention: Kinemyography (KMG)
Description: Measurement of the muscle velocity for the assessment of neuromuscular function

Intervention type: DEVICE
Intervention: Kinemyography (KMG)
Description: Measurement of the muscle velocity for the assessment of neuromuscular function

Intervention type: DEVICE
Intervention: Kinemyography (KMG)
Description: Measurement of the muscle velocity for the assessment of neuromuscular function

Intervention type: DEVICE
Intervention: Kinemyography (KMG)
Description: Measurement of the muscle velocity for the assessment of neuromuscular function
Study: NCT04764461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of customised GROW Charts
Description: Intervention group will follow the same antenatal visit plan and two ultrasounds will be offered (NT 11-13+6 weeks \& anomaly scan 19-22 weeks of gestation) in routine. A third trimester scan will not be offered in routine to Intervention group. Serial SFH measurements will be plotted against estimated date of delivery at each review from 26 weeks of gestation on the customized GROW chart already attached in the maternity notes. On each visit patient will be examined after emptying bladder in a semi-recumbent position, using non-elastic tape with cm side hidden; measurement will be taken from the fundus to upper margin of pubic symphysis. Abnormal SFH measurements, when plotted below the 10th or does not follow its trajectory on customized growth charts will be referred for growth scan suspecting SGA. SFH plotted above 90th centile will also be referred for growth scan, as a part of antenatal care.
Study: NCT04490967

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Description: Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Study: NCT05599503

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Interventions
Description: Traditional SimpleC Wellness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interventions
Description: Traditional SimpleC Wellness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot Interventions
Description: Robot interventions
Study: NCT05601232

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT
Description: Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
Study: NCT04836429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo VATS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo photodynamic therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative PDT
Description: Subjects will receive one course of light therapy at the time of surgery
Study: NCT05869708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active RS-EFP
Description: A minimum of 10 and up to 15 active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RS-EFP
Description: a minimum of 10 and up to 15 sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
Study: NCT03838887

Intervention type: DEVICE
Intervention: ultrasound machine
Description: Ultrasound machine with a vocal software

Intervention type: DEVICE
Intervention: ultrasound machine
Description: Ultrasound machine with a vocal software
Study: NCT05444569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537021
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537021
Description: Administered SC.
Study: NCT05198869

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral scan
Description: Consenting participants will have a SpotLight-19 scan
Study: NCT05428501

Intervention type: OTHER
Intervention: no treatment given
Description: People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)

Intervention type: OTHER
Intervention: no treatment given
Description: People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
Study: NCT04477759

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50 Gy Radiation Therapy
Description: Ionizing radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 55 Gy Radiation Therapy
Description: Ionizing radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60 Gy Radiation Therapy
Description: Ionizing radiation
Study: NCT05444569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537021
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SC.
Study: NCT04477759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
Study: NCT04733638

Intervention type: DEVICE
Intervention: Viz ICH VOLUME
Description: Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
Study: NCT04905134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngoscope
Description: Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngoscope
Description: Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
Study: NCT05444569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SC.
Study: NCT04959435

Intervention type: OTHER
Intervention: biological samples collection
Description: samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa

Intervention type: OTHER
Intervention: biological samples collection
Description: samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
Study: NCT04523714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT-CP based program
Description: Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual coach-led CBT-CP based program
Description: Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
Study: NCT05372757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Heart Transplantation
Description: The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
Study: NCT05254626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
Study: NCT06061094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 600mg QD plus Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 600mg QD plus Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 600mg QD plus Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg QD plus chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg QD plus chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg QD plus chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indication for stem cell transplantation
Description: Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indication for stem cell transplantation
Description: Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
Study: NCT05139472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Daily Empagliflozin